T

he European Commission has opened a formal investigation into Aspen Pharma over allegations the drug maker engaged in price gouging for five life-saving cancer medicines, marking the first EC probe into excessive pricing in the pharmaceutical industry.

The move, which was urged last month by consumer advocacy groups in Europe, comes after Italian antitrust authorities last October fined the drug maker $5.5 million for halting supplies of several cancer drugs as a negotiating tactic designed to boost prices by as much as 1,500 percent.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Please stop sending me messages.. Seeing as I am not a member and never will be. Thank you very much and have a nice day!

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.